LUX Infusion, a clinician-led infusion service network, announced the availability of Qfitlia (fitusiran), which will not only broaden treatment access but also provide clinical support for patients living with hemophilia A or B.

For patients 12 years and older with hemophilia A or B with or without Factor VIII or IX inhibitors that require routine bleed prevention treatment, Qfitlia is a subcutaneous treatment option. LUX Infusion is integrating the therapy into a care framework purpose-built to eliminate access barriers for patients.

"Making care easier to not only access, but also navigate is central to our mission," said Ted Kramm, Chief Executive Officer of LUX Infusion. "We hold a deep, long-standing commitment to the bleeding disorder community, and adding Qfitlia to our portfolio enables us to offer a unique treatment option that is fully supported by our high-touch model."

Whether starting Qfitlia as a new patient or transitioning as an established patient to LUX Infusion, patients receive support throughout the treatment process. This means LUX Infusion not only helps patients navigate the initial barriers to treatment with a benefits and appeals team but also provides assistance to patients at every step of the day-to-day treatment journey.

The Company's bleeding disorder program is uniquely designed to work closely with patients and their Hemophilia Treatment Centers (HTCs), pairing every patient with a single point of contact that has real-world bleeding disorder experience, backed by 24/7 on-call guidance.